Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARD | Q03181 | 2/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | FDPS | P14324 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3338817 | 0.85 | FDPS (0.31) | FDPSLMNA | |
| SCHEMBL2234946 | 0.85 | PPARD (0.44) | PPARDTSHRMEN1GAACYP2C9 | |
| SCHEMBL3345788 | 0.84 | PPARD (0.42) | PPARDTSHRMEN1GAACYP2C9 | |
| SCHEMBL3343248 | 0.80 | PPARD (0.47) | PPARDTSHRMEN1GAACYP2C9 | |
| SCHEMBL3342044 | 0.74 | PPARD (0.44) | PPARDTSHRMEN1GAACYP2C9 | |
| SCHEMBL3342997 | 0.73 | PPARD (0.47) | PPARDTSHRMEN1GAACYP2C9 | |
| SCHEMBL2234204 | 0.71 | PPARD (0.41) | PPARDTSHRMEN1GAACYP2C9 | |
| SCHEMBL16352174 | 0.71 | PPARD (0.48) | PPARDTSHRMEN1KMT2ATP53 | |
| SCHEMBL13624819 | 0.70 | PPARD (0.58) | PPARDTSHRMEN1GAACYP2C9 | |
| SCHEMBL9003229 | 0.70 | PPARD (0.52) | PPARDTSHRMEN1GAACYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8182789-B2 | Intermediate compound of technetium nitride complex for radiodiagnostic imaging | NIHON MEDI-PHYSICS CO., LTD. (JP) | 2012-05-22 | — | — | US | disclosed |
| EP-1973923-B1 | INTERMEDIATE COMPOUND OF TECHNETIUM NITRIDE COMPLEX FOR RADIODIAGNOSTIC IMAGING | NIHON MEDIPHYSICS CO LTD (JP) | 2011-08-17 | — | — | EP | disclosed |
| US-20100160615-A1 | INTERMEDIATE COMPOUND OF TECHNETIUM NITRIDE COMPLEX FOR RADIODIAGNOSTIC IMAGING | NIHON MED-PHYSICS CO., LTD. (JP) | 2010-06-24 | — | — | US | disclosed |
| WO-2006080993-A1 | NOVEL CATIONIC METAL COMPLEX RADIOPHARMACEUTICALS | PURDUE RESEARCH FOUNDATION (US) | 2006-08-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100160615-A1 | INTERMEDIATE COMPOUND OF TECHNETIUM NITRIDE COMPLEX FOR RADIODIAGNOSTIC IMAGING | MEN1, NCDN, C1R | PPARD 2640/4885TSHR 33/4885MEN1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.